胰高血糖素样肽-1受体激动剂对糖尿病及非糖尿病患者上消化道内镜的影响
该回顾性研究纳入2019至2023年接受食管胃十二指肠镜(EGD)的35183例患者,其中922例使用胰高血糖素样肽-1受体激动剂(GLP-1 RA)。GLP-1 RA使用与胃内容物滞留增加4倍、EGD中止率升高4倍及需重复EGD的可能性加倍相关,且按糖尿病状态分层后仍存在。
要点
- GLP-1 RA使用与EGD中胃内容物滞留增加4倍相关(P < .0001)。
- GLP-1 RA使用与EGD中止率升高4倍相关(P < .0001)。
- GLP-1 RA使用与需重复EGD的可能性加倍相关(P = .0001)。
核心结论
- GLP-1 RA使用可导致胃排空延迟,无论是否存在糖尿病均影响EGD的充分性,可能需调整剂量以改善操作的安全性和有效性。
研究设计与样本
- 回顾性研究,纳入2019至2023年间接受EGD的35183例患者,其中922例使用GLP-1 RA。
主要发现
- GLP-1 RA使用与胃内容物滞留增加4倍相关(P < .0001)。
- GLP-1 RA使用与EGD中止率升高4倍相关(P < .0001)。
- GLP-1 RA使用与需重复EGD的可能性加倍相关(P = .0001)。
- 按糖尿病状态分层后,上述关联仍存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) promote weight loss by suppressing appetite, enhancing satiety, regulating glucose metabolism, and delaying gastric motility. We sought to determine whether GLP-1 RA use could affect medical procedures such as EGD. METHODS: We conducted a retrospective study of 35,183 patients who underwent EGD between 2019 and 2023, 922 of whom were using a GLP-1 RAs. Data were collected regarding demographics, diabetes status, retained gastric contents during EGD, incidence of aborted EGD, and necessity for repeat EGD. RESULTS: GLP-1 RA use was associated with a 4-fold increase in the retention of gastric contents (P < .0001), 4-fold higher rates of aborted EGD (P < .0001), and twice the likelihood of requiring repeat EGD (P = .0001), even after stratifying for the presence of diabetes. CONCLUSIONS: GLP-1 RA use can lead to delayed gastric emptying, affecting EGD adequacy regardless of the presence of diabetes, and may warrant dose adjustment to improve the safety and efficacy of these procedures.
引用
- Nadeem D, Taye M, Still MD, et al. Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients. Gastrointest Endosc. 2024. PMID: 38692518. doi:10.1016/j.gie.2024.04.2900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。